Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2016 Mar;22(3):449-55. doi: 10.1016/j.bbmt.2015.10.018. Epub 2015 Nov 2.

Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

Author information

1
Division of Hematology, Oncology and Transplant, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: arora005@umn.edu.
2
Division of Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
3
Division of Hematology and Stem Cell Transplant, Vanderbilt University Medical Center, Nashville, Tennessee.
4
Blood and Marrow Transplantation Program, Moffitt Cancer Center, Tampa, Florida.
5
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
6
Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
7
BMT Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
8
Division of Hematology and Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina.
9
Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
10
Division of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
11
Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California.
12
Division of Hematology and Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, New York.
13
Section of Bone Marrow Transplant and Leukemia, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.

Abstract

Several distinct graft-versus-host disease (GVHD)-related syndromes have been defined by the National Institutes of Health Consensus Conference. We enrolled a prospective cohort of 911 hematopoietic cell transplantation (HCT) recipients at 13 centers between March 2011 and May 2014 to evaluate 4 GVHD syndromes: late acute GVHD (aGVHD), chronic GVHD (cGVHD), bronchiolitis obliterans syndrome, and cutaneous sclerosis. The median age at HCT was 53.7 years. The majority of patients received a peripheral blood stem cell transplant (81%) following nonmyeloablative or reduced-intensity conditioning (55%). Pediatric age group and use of bone marrow and umbilical cord blood grafts were underrepresented in our cohort (≤11%). The cumulative incidence of late aGVHD (late onset and recurrent) was 10% at a median of 5.5 months post-HCT, that of cGVHD was 47% at a median of 7.4 months, that of bronchiolitis obliterans was 3% at a median of 12.2 months, and that of cutaneous sclerosis was 8% at a median onset of 14.0 months. Late aGVHD and bronchiolitis obliterans had particularly high nonrelapse mortality of 23% and 32%, respectively, by 2 years after diagnosis. The probability of late aGVHD- and cGVHD-free, relapse-free survival was 38% at 1 year post-HCT and 26% at 2 years post-HCT. This multicenter prospective study confirms the high rate of late aGVHD and cGVHD syndromes and supports the need for continuous close monitoring and development of more effective GVHD treatment strategies to improve HCT success.

KEYWORDS:

Bronchiolitis obliterans syndrome; Chronic graft-versus-host disease; Cutaneous sclerosis; Graft-versus-host disease syndromes; Hematopoietic cell transplantation; Late acute graft-versus-host disease

PMID:
26541363
PMCID:
PMC4787270
[Available on 2017-03-01]
DOI:
10.1016/j.bbmt.2015.10.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center